Weight regain after Mounjaro means reversal of health benefits, finds study Regaining weight after stopping taking weight loss jab tirzepatide (Mounjaro) is also associated with a reversal in the cardiovascular health benefits, researchers have reported
This analysis uses 2023 Medicare claims for traditional Medicare, Medicare Advantage encounter data, and Part D prescription drug event data to estimate the total number of Medicare beneficiaries with obesity or overweight, the number of Part D enrollees who met the Bridge eligibility criteria in 2023, and those who met the Bridge clinical criteria but who also had diagnoses recorded in claims or encounter data that would qualify for Part D coverage of GLP-1s (type 2 diabetes, OSA, or MASH) or who had a GLP-1 Part D-covered prescription during the year, either of which would make them ineligible for Bridge (see Methods)
The current lower-dose formulations of semaglutide have been around for years at this point, and their high list prices (around $1,000 per month) have angered both the public and lawmakers
Semaglutide injections are not advised for individuals with a history of thyroid cancer, pancreatitis, or specific gastrointestinal conditions
those with eGFR below 45, severe dehydration risk, or prior acute kidney injury should avoid this combination
Obesity In addition to diabetes, Semaglutide is also approved for chronic weight management